An Open-label, Multi-center, Randomized Study of the Safety and Effect on Event-free Survival of Bevacizumab in Combination With Standard Chemotherapy in Childhood and Adolescent Patients With Metastatic Rhabdomyosarcoma and Non-rhabdomyosarcoma Soft Tissue Sarcoma

Trial Profile

An Open-label, Multi-center, Randomized Study of the Safety and Effect on Event-free Survival of Bevacizumab in Combination With Standard Chemotherapy in Childhood and Adolescent Patients With Metastatic Rhabdomyosarcoma and Non-rhabdomyosarcoma Soft Tissue Sarcoma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Jul 2017

At a glance

  • Drugs Bevacizumab (Primary)
  • Indications Ewing's sarcoma; Rhabdomyosarcoma; Sarcoma; Soft tissue sarcoma
  • Focus Therapeutic Use
  • Acronyms BERNIE
  • Sponsors Roche
  • Most Recent Events

    • 12 Jul 2017 Primary endpoint (Percentage of Participants Who Experienced Event-Free Survival (EFS) Events as Per Independent Review Committee (IRC) Assessment) has not been met, as per results published in the European Journal of Cancer.
    • 12 Jul 2017 Results published in the European Journal of Cancer
    • 06 Jun 2017 Results of an integrated analysis assessing the effects of bevacizumab on growth/development in pediatric/adolescent patients (n=403), presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top